Pharmafile Logo

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

April 29, 2024 | Insights, US, healthcare, market research 

- PMLiVE

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and client management. Throughout her career, Kathy has worked extensively at guiding her clients to identify the optimal research approach to address the business issue at hand. In Kathy’s most recent position as Senior Vice President, Business Development at ThinkGen, she was responsible for implementing the business development and marketing strategy and overseeing all client outreach.

In 2023, Kathy was honored with the Healthcare Businesswomen’s Association (HBA) Luminary Award which recognizes professionals who have made a significant impact on the healthcare industry and have a proven track record of helping advance careers of other women. Kathy also volunteered as a HBA mentor as part of the HBA Mentoring Program.

In this pivotal role at Research Partnership, Kathy will be working with our Commercial Team to identify new business opportunities, nurture existing partnerships and enhance our US based presence in the market.  

US President, Sue Wild commented “I am delighted to welcome Kathy to the team, she has extensive experience and will be instrumental in nurturing our client relationships in the US market. I look forward to collaborating with Kathy to strengthen our offerings in delivering the best possible insights for our valued clients”.

Find out more. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...